NCT02955641

Efficacy and Necessity of Anti-inflammatory Drops After Laser Peripheral Iridotomy

• Status: Unknown
• Phase: N/A
• Study type: Interventional
• Enrollment: 100 (estimated)
• Sponsor: Sheba Medical Center · Other Government
• Sex: All
• Age: 18 Years – 90 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to evaluate the efficacy and need for prescribing anti-inflammatory topical drops to patients undergoing laser peripheral iridotomy.

Detailed description

Primary closed angle glaucoma is responsible to almost half glaucoma related blindness around the world. Laser peripheral iridotomy (LPI) is a common and simple treatment used for both treatment and prevention of acute angle closure event. Anti-inflammatory drops are commonly prescribed to patients undergoing LPI in order to prevent or reduce post-treatment discomfort. However, to date, there are no specific guidelines for post LPI anti-inflammatory treatment, nor sufficient clinical evidence regarding the efficacy of such treatment. In the current study, the investigators aim to evaluate the effect of topical steroids and non-steroidal anti-inflammatory drugs (NSAIDs) on post LPI symptoms and inflammation markers.

Conditions

• Glaucoma, Closed-Angle
• Glaucoma, Narrow-Angle
• Glaucoma, Angle-Closure

Interventions

Type	Name	Description
DRUG	Dexamethasone Disodium Phosphate 0.1%	four drops a day for four days after LPI treatment
DRUG	Nepafenac 0.1%	four drops a day for four days after LPI treatment
DRUG	Hydroxyethylcellulose 0.19%	four drops a day for four days after LPI treatment

Timeline

• Start date: 2016-11-01
• Primary completion: 2018-11-01
• Completion: 2019-11-01
• First posted: 2016-11-04
• Last updated: 2018-04-24

Locations

1 site across 1 country: Israel